To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

COPDHealthy Subjects

Interventions

DRUG

AZD7624

Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer

DRUG

Placebo to match

Multiple doses inhaled placebo via a nebulizer

Trial Locations (1)

Research Site, London